𝔖 Bobbio Scriptorium

✦ LIBER ✦

Corrigendum to: “A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Extracorporeal Shock Wave Therapy for the Treatment of Peyronie's Disease” [Eur Urol 2009;56:363-70]

✍ Scribed by Alessandro Palmieri; Ciro Imbimbo; Nicola Longo; Ferdinando Fusco; Paolo Verze; Francesco Mangiapia; Massimiliano Creta; Vincenzo Mirone

Book ID: 113611581
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 55 KB
Volume: 56
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2009.07.039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A First Prospective, Randomized, Double-

A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Extracorporeal Shock Wave Therapy for the Treatment of Peyronie's Disease

✍ Alessandro Palmieri; Ciro Imbimbo; Nicola Longo; Ferdinando Fusco; Paolo Verze; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 827 KB

Re: Reinhold Zimmermann, Alin Cumpanas,

Re: Reinhold Zimmermann, Alin Cumpanas, Florin Miclea, Günter Janetschek. Extracorporeal Shock Wave Therapy for the Treatment of Chronic Pelvic Pain Syndrome in Males: A Randomised, Double-Blind Placebo-Controlled Study. Eur Urol 2009;56:418–24

✍ Tommaso Cai; Riccardo Bartoletti 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Reply to Tommaso Cai and Riccardo Bartol

Reply to Tommaso Cai and Riccardo Bartoletti's Letter to the Editor re: Reinhold Zimmermann, Alin Cumpanas, Florin Miclea, Günter Janetschek. Extracorporeal Shock Wave Therapy for the Treatment of Chronic Pelvic Pain Syndrome in Males: A Randomised, Double-Blind, Placebo-Controlled Study. Eur Urol 2009;56:418–24

✍ Reinhold P. Zimmermann; Günther Janetschek 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB